doi: 10.1038/ng0694-180.
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Affiliations
- PMID:7920638
- DOI: 10.1038/ng0694-180
Item in Clipboard
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
E H Corder et al. Nat Genet.1994 Jun.
Display options
Format
Display options
Format
Abstract
Gene dosage of the apolipoprotein E (APOE) epsilon 4 allele is a major risk factor for familial Alzheimer disease (AD) of late onset (after age 60). Here we studied a large series of 115 AD case subjects and 243 controls as well as 150 affected and 197 unaffected members of 66 AD families. Our data demonstrate a protective effect of the epsilon 2 allele, in addition to the dose effect of the epsilon 4 allele in sporadic AD. Although a substantial proportion (65%) of AD is attributable to the presence of epsilon 4 alleles, risk of AD is lowest in subjects with the epsilon 2/epsilon 3 genotype, with an additional 23% of AD attributable to the absence of an epsilon 2 allele. The opposite actions of the epsilon 2 and epsilon 4 alleles further support the direct involvement of APOE in the pathogenesis of AD.
Similar articles
- Gene polymorphism in apolipoprotein E and presenilin-1 in patients with late-onset Alzheimer's disease.Cui T, Zhou X, Jin W, Zheng F, Cao X.Cui T, et al.Chin Med J (Engl). 2000 Apr;113(4):340-4.Chin Med J (Engl). 2000.PMID:11775232
- Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease.Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, et al.Saunders AM, et al.Neurology. 1993 Aug;43(8):1467-72. doi: 10.1212/wnl.43.8.1467.Neurology. 1993.PMID:8350998
- Allele doses of apolipoprotein E type epsilon 4 in sporadic late-onset Alzheimer's disease.Lucotte G, Aouizérate A, Gérard N, Turpin JC, Landais P.Lucotte G, et al.Am J Med Genet. 1995 Dec 18;60(6):566-9. doi: 10.1002/ajmg.1320600617.Am J Med Genet. 1995.PMID:8825898
- [Alzheimer disease: hypotheses implicating apolipoproteins E].Blain H, Merched A, Visvikis S, O'Kane M, Pillot T, Siest G, Jeandel C.Blain H, et al.Presse Med. 1996 May 4-11;25(16):763-8.Presse Med. 1996.PMID:8692753Review.French.
- Apolipoprotein E genotype in the prediction of cognitive decline and dementia in a prospectively studied elderly population.Brayne C, Harrington CR, Wischik CM, Huppert FA, Chi LY, Xuereb JH, O'Connor DW, Paykel ES.Brayne C, et al.Dementia. 1996 May-Jun;7(3):169-74. doi: 10.1159/000106873.Dementia. 1996.PMID:8740632Review.
Cited by
- APOE2 mitigates disease-related phenotypes in an isogenic hiPSC-based model of Alzheimer's disease.Brookhouser N, Raman S, Frisch C, Srinivasan G, Brafman DA.Brookhouser N, et al.Mol Psychiatry. 2021 Oct;26(10):5715-5732. doi: 10.1038/s41380-021-01076-3. Epub 2021 Apr 9.Mol Psychiatry. 2021.PMID:33837271Free PMC article.
- APOε2 and education in cognitively normal older subjects with high levels of AD pathology at autopsy: findings from the Nun Study.Iacono D, Zandi P, Gross M, Markesbery WR, Pletnikova O, Rudow G, Troncoso JC.Iacono D, et al.Oncotarget. 2015 Jun 10;6(16):14082-91. doi: 10.18632/oncotarget.4118.Oncotarget. 2015.PMID:26101858Free PMC article.
- Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly.Randall C, Mosconi L, de Leon M, Glodzik L.Randall C, et al.Front Biosci (Landmark Ed). 2013 Jun 1;18(3):1150-73. doi: 10.2741/4170.Front Biosci (Landmark Ed). 2013.PMID:23747874Free PMC article.Review.
- Cognitive reserve and midlife vascular risk: Cognitive and clinical outcomes.Soldan A, Pettigrew C, Zhu Y, Wang MC, Gottesman RF, DeCarli C, Albert M; BIOCARD Research Team.Soldan A, et al.Ann Clin Transl Neurol. 2020 Aug;7(8):1307-1317. doi: 10.1002/acn3.51120. Epub 2020 Jul 21.Ann Clin Transl Neurol. 2020.PMID:32856790Free PMC article.
- Using lipid profiling to better characterize metabolic differences in apolipoprotein E (APOE) genotype among community-dwelling older Black men.Marron MM, Moore SC, Wendell SG, Boudreau RM, Miljkovic I, Sekikawa A, Newman AB.Marron MM, et al.Geroscience. 2022 Apr;44(2):1083-1094. doi: 10.1007/s11357-021-00382-6. Epub 2021 May 15.Geroscience. 2022.PMID:33991295Free PMC article.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous